Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Akshay S DesaiDavid J WebbJorg TaubelSarah CaseyYansong ChengGabriel J RobbieDon FosterStephen A HuangSean RhyeeMarianne T SweetserGeorge L BakrisPublished in: The New England journal of medicine (2023)
Dose-dependent decreases in serum angiotensinogen levels and 24-hour ambulatory blood pressure were sustained for up to 24 weeks after a single subcutaneous dose of zilebesiran of 200 mg or more; mild injection-site reactions were observed. (Funded by Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT03934307; EudraCT number, 2019-000129-39.).